

March 29, 2025

<p><b>The Secretary, National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051</b></p> <p><b>NSE Code: ARTEMISMED</b></p>	<p><b>The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</b></p> <p><b>Scrip Code: 542919</b></p>
---	---

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

Dear Sir/Ma’am,

Pursuant to Regulation 30 of the SEBI Listing Regulations, this is to inform that the Company has received cautionary emails from BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), on March 28, 2025 at 04:30 P.M. and 07:01 P.M., respectively, regarding delay in submission of intimation of schedule of Investors/ Analysts Meeting held on June 21, 2024.

Copies of the cautionary email as received from BSE and NSE are enclosed herewith.

The details as required under the SEBI Listing Regulations, are provided in “Annexure-A”.

Please note that in the intimation submitted by the Company on June 19, 2024, it was mentioned that the meeting was scheduled at a shorter notice, due to an unanticipated conflict in schedule of participants at a later date. Further, the Company had already taken necessary steps to avoid recurrence of such lapses in future.

Submitted for your information & records.

Thanking you.

Yours faithfully,  
**For Artemis Medicare Services Limited**

**Poonam Makkar**  
**Company Secretary & Compliance Officer**

**Encl.: As above**



**Annexure-A**

Sr. No.	Particulars	Details
1.	Name of the authority	BSE Limited (BSE) and National Stock Exchange of India Limited (NSE)
2.	Nature and details of the action(s) taken or order(s) passed	Cautionary email
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	March 28, 2025
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Delay in submission of intimation of Schedule of Investors/ Analysts Meeting.  Investors/ Analysts Meeting scheduled for June 21, 2024, was intimated to BSE and NSE on June 19, 2024, with a delay of one working day.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the financial, operation or other activities of the Company.



## Poonam Makkar

---

**From:** Query lodr <query.lodr@bseindia.com>  
**Sent:** 28 March 2025 16:30  
**To:** Poonam Makkar  
**Subject:** Cautionary Letter

**EXTERNAL EMAIL:** This email originated from outside the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe. Please treat hyperlinks, attachments and instructions in this email with extreme caution.

LIST/COMP/JP/1790/2024-25  
March 28, 2025

Date:

To,  
Company Secretary /Compliance Officer  
**Artemis Medicare Services Ltd (542919)**

### Sub: Cautionary letter

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 19, 2024, regarding the intimation of Schedule of Investors/ Analysts' Meet/ Call to be held on June 21, 2024

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR'), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet/call).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary Letter on the Stock Exchanges where they are listed. Additionally, the Company is advised to place before their Board of Directors this Cautionary Letter and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

Yours faithfully,

Listing Compliance Monitoring Team

**BSE Limited**

P J Towers, Dalal Street,  
Mumbai - 400001, India

[www.bseindia.com](http://www.bseindia.com)

Tel: 022 2272 8561 / 8475

## Poonam Makkar

---

**From:** neaps@nse.co.in  
**Sent:** 28 March 2025 19:01  
**To:** Poonam Makkar  
**Subject:** ARTEMISMED- Cautionary Email

**EXTERNAL EMAIL:** This email originated from outside the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe. Please treat hyperlinks, attachments and instructions in this email with extreme caution.

Dear Sir/Madam,

This is in reference to the announcement submitted by the Company on June 19, 2024 regarding the intimation of Schedule of Investors/ Analysts Meet/call to be held on June 21, 2024.

As per Regulation 30 read with sub-para 15(a) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI LODR ), the listed entities are required to disclose the schedule of analysts or institutional investors meet at least two working days in advance (excluding the date of the intimation and the date of the meet).

In the above case, the Exchange has observed that the aforesaid intimation was not submitted within the prescribed timelines of two working days in advance as per sub-para 15(a) of Para A of Part A of Schedule III of SEBI LODR.

The aforesaid non-compliance on your part is viewed seriously. You are hereby advised to be cautious in future, exercise due diligence and initiate corrective steps to avoid recurrence of such lapses so as to ensure due compliance with the applicable provisions of SEBI LODR and related SEBI circulars. Any aberration in future will be viewed seriously and appropriate action would be initiated.

The Company is required to disseminate a copy of this Cautionary email on the Stock Exchanges where they are listed.

Additionally, the Company is advised to place before their Board of Directors this Cautionary email and the corrective measures taken by the Company to avoid recurrence of such lapses in future.

This is system generated email, you may reach out to the Announcements Team in case of any assistance at takeover@nse.co.in.